<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Springerplus</journal-id><journal-id journal-id-type="iso-abbrev">Springerplus</journal-id><journal-title-group><journal-title>SpringerPlus</journal-title></journal-title-group><issn pub-type="epub">2193-1801</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25105088</article-id><article-id pub-id-type="pmc">4124105</article-id><article-id pub-id-type="publisher-id">1088</article-id><article-id pub-id-type="doi">10.1186/2193-1801-3-389</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Effects of combined netupitant and palonosetron (NEPA), a cancer supportive care antiemetic, on the ECG of healthy subjects: an ICH E14 thorough QT trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Spinelli</surname><given-names>Tulla</given-names></name><address><email>tulla.spinelli@helsinn.com</email></address><xref ref-type="aff" rid="Aff13"/></contrib><contrib contrib-type="author"><name><surname>Moresino</surname><given-names>Cecilia</given-names></name><address><email>Cecilia.Moresino@helsinn.com</email></address><xref ref-type="aff" rid="Aff13"/></contrib><contrib contrib-type="author"><name><surname>Baumann</surname><given-names>Sybille</given-names></name><address><email>Sybille.Baumann@crs-group.de</email></address><xref ref-type="aff" rid="Aff14"/></contrib><contrib contrib-type="author"><name><surname>Timmer</surname><given-names>Wolfgang</given-names></name><address><email>w.timmer@inamed-cro.com</email></address><xref ref-type="aff" rid="Aff14"/></contrib><contrib contrib-type="author"><name><surname>Schultz</surname><given-names>Armin</given-names></name><address><email>armin.schultz@crs-group.de</email></address><xref ref-type="aff" rid="Aff14"/></contrib><aff id="Aff13"><label/>Helsinn Healthcare SA, Via Pian Scairolo 9, 6912 Lugano/Pazzallo, Switzerland
</aff><aff id="Aff14"><label/>CRS Clinical Research Services Mannheim GmbH, Grenadierstrasse 1, 68167 Mannheim, Germany
</aff></contrib-group><pub-date pub-type="epub"><day>29</day><month>7</month><year>2014</year></pub-date><pub-date pub-type="pmc-release"><day>29</day><month>7</month><year>2014</year></pub-date><pub-date pub-type="collection"><year>2014</year></pub-date><volume>3</volume><elocation-id>389</elocation-id><history><date date-type="received"><day>10</day><month>4</month><year>2014</year></date><date date-type="accepted"><day>17</day><month>7</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; Spinelli et al.; licensee Springer. 2014</copyright-statement><license license-type="open-access"><license-p>This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.</license-p></license></permissions><abstract id="Abs1"><p>Chemotherapy-induced nausea and vomiting is ranked among the worst side effects of chemotherapy. NEPA is an oral fixed-dose combination antiemetic under development, consisting of netupitant 300 mg, a highly selective NK<sub>1</sub> receptor antagonist (RA), and palonosetron 0.5 mg, a pharmacologically and clinically distinct 5-HT<sub>3</sub> RA. Although palonosetron is not associated with relevant ECG effects, this study evaluated cardiovascular safety of netupitant in combination with palonosetron, as well as its tolerability.</p><p>This randomised, placebo- and positively controlled study in 197 subjects included 4 treatment groups: placebo, 200 mg netupitant + 0.5 mg palonosetron (NEPA<sub>200/0.5</sub>), 600 mg netupitant + 1.5 mg palonosetron (NEPA<sub>600/1.5</sub>, a supratherapeutic dose), and 400 mg moxifloxacin. Assessments included a 24-h baseline ECG recording, followed by a single dose of treatment and ECG measurements for 2 days.</p><p>Mean placebo-corrected time-averaged changes from baseline were similar in NEPA<sub>200/0.5</sub> and NEPA<sub>600/1.5</sub> groups primarily for individually heart rate-corrected QT interval (QTcI: +4.7 and +3.6 ms, respectively) and for heart rate (HR: &#x02013;3.3 bpm and &#x02013;3.0 bpm), PR interval (&#x02013;0.4 ms and 0.2 ms), and QRS interval (1 ms and 0.5 ms). The time-matched analysis showed no upper confidence interval &#x0003e;10 ms, with no suggestion of a QTc effect by pharmacokinetic-pharmacodynamic modeling for parent/metabolites. Moxifloxacin showed the expected placebo-corrected change from baseline (+8.4 ms time average) and the expected profile to establish assay sensitivity. No new morphologic changes of clinical relevance were observed. Treatment-related adverse events were comparable among groups.</p><p>This study showed that NEPA treatments produced no significant effects on QTcI, HR, PR interval, QRS interval, and cardiac morphology relative to placebo, even at supratherapeutic doses.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>NEPA</kwd><kwd>Chemotherapy-induced nausea and vomiting</kwd><kwd>Netupitant</kwd><kwd>Palonosetron</kwd><kwd>QTc</kwd><kwd>ECG</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2014</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>Chemotherapy-induced nausea and vomiting (CINV) is a common and distressing consequence of cytotoxic chemotherapy. Acute CINV is described as CINV occurring in the first 24&#x000a0;hours after administration of chemotherapy, whereas delayed CINV begins 25&#x000a0;hours or more after chemotherapy initiation, and can last up to several days after chemotherapy is completed (Bloechl-Daum et al. <xref ref-type="bibr" rid="CR10">2006</xref>; Hesketh et al. <xref ref-type="bibr" rid="CR24">2003</xref>). CINV impacts patients&#x02019; quality of life and is a major reason for noncompletion or delay of the chemotherapy programme (Bloechl-Daum et al. <xref ref-type="bibr" rid="CR10">2006</xref>; Aapro et al. <xref ref-type="bibr" rid="CR3">2012</xref>; Cohen et al. <xref ref-type="bibr" rid="CR13">2007</xref>).</p><p>There are 2 major pathways known to be involved in CINV. The neurotransmitter serotonin (5-hydroxytryptamine or 5-HT) has been shown to be an important mediator of the acute phase, while the role of substance P is mainly related to the delayed phase of CINV (Hesketh et al. <xref ref-type="bibr" rid="CR24">2003</xref>; Rojas and Slusher <xref ref-type="bibr" rid="CR33">2012</xref>; Feyer and Jordan <xref ref-type="bibr" rid="CR17">2011</xref>; Rubenstein et al. <xref ref-type="bibr" rid="CR35">2006</xref>). Preclinical studies demonstrated that cisplatin causes increased levels in the peripheral circulation of both serotonin and substance P. The 5-HT<sub>3</sub> receptor antagonists (RAs) are thought to inhibit the serotonin emetic pathway peripherally, while the neurokinin 1 (NK<sub>1</sub>) RAs are thought to act on the substance P-mediated signaling at the level of the central nervous system (Hesketh et al. <xref ref-type="bibr" rid="CR24">2003</xref>; Rojas and Slusher <xref ref-type="bibr" rid="CR33">2012</xref>; Feyer and Jordan <xref ref-type="bibr" rid="CR17">2011</xref>; Rubenstein et al. <xref ref-type="bibr" rid="CR35">2006</xref>).</p><p>International antiemetic guidelines recommend administering a 5-HT<sub>3</sub> RA with an NK<sub>1</sub> RA and a corticosteroid as part of the antiemetic regimen to prevent nausea and vomiting in patients who are at high risk to develop it (Basch et al. <xref ref-type="bibr" rid="CR8">2011</xref>; Gralla et al. <xref ref-type="bibr" rid="CR20">2013</xref>; Roila et al. <xref ref-type="bibr" rid="CR32">2010</xref>; National Comprehensive Cancer Network <xref ref-type="bibr" rid="CR30">2013</xref>). Nevertheless, CINV is still underestimated, particularly in the delayed phase and with regard to nausea (Bloechl-Daum et al. <xref ref-type="bibr" rid="CR10">2006</xref>; Cohen et al. <xref ref-type="bibr" rid="CR13">2007</xref>; Salsman et al. <xref ref-type="bibr" rid="CR37">2012</xref>; Roscoe et al. <xref ref-type="bibr" rid="CR34">2004</xref>). This represents an area of need that should be addressed by new and safe antiemetics.</p><p>NEPA is a new antiemetic under development that targets a dual antiemetic pathway with a single oral fixed-dose combination of netupitant 300&#x000a0;mg and palonosetron 0.5&#x000a0;mg to be administered prior to emetogenic chemotherapy. The phase II and III pivotal clinical studies demonstrating both the safety and high efficacy of this convenient single-day antiemetic have recently been published (Hesketh et al. <xref ref-type="bibr" rid="CR25">2014</xref>; Aapro et al. <xref ref-type="bibr" rid="CR4">2014</xref>; Gralla et al. <xref ref-type="bibr" rid="CR21">2014</xref>). Netupitant (2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-[6-(4-methyl-piperazin-1-yl)-4-o-tolyl-pyridine-3-yl]-isobutyramide) is a new and selective NK<sub>1</sub> RA showing a high receptor occupancy level at time to maximum plasma concentration (t<sub>max</sub>; more than 90%) and a long-lasting (up to 96&#x000a0;hours postdose) blockade of NK<sub>1</sub> receptors in the human brain (Spinelli et al. <xref ref-type="bibr" rid="CR39">2014</xref>). Chronic administration of different daily doses of netupitant (50&#x000a0;mg, 100&#x000a0;mg, and 200&#x000a0;mg) for 8&#x000a0;weeks raised no safety issues in patients with an overactive bladder (Haab et al. <xref ref-type="bibr" rid="CR22">2014</xref>). Palonosetron ((3aS)-2-[(S)-1-Azabicyclo[2.2.2]oct-3-yl]-2,3,3a,4,5,6-hexahydro-1-oxo-1Hbenz[de]isoquinoline hydrochloride) is a 5-HT<sub>3</sub> RA with a longer half-life and higher binding affinity that differs from traditional setrons both from a pharmacologic and clinical point of view (Reddy et al. <xref ref-type="bibr" rid="CR31">2006</xref>). In vitro and in vivo studies demonstrated that palonosetron uniquely: 1) exhibits allosteric binding to the 5-HT<sub>3</sub> receptor, with positive cooperativity and persistent inhibition of receptor function; 2) triggers 5-HT<sub>3</sub> receptor internalisation; and 3) inhibits substance P-mediated response through inhibition of the 5-HT<sub>3</sub> and NK<sub>1</sub> receptor cross-talk (Rojas and Slusher <xref ref-type="bibr" rid="CR33">2012</xref>). Several studies have shown that palonosetron, as a single agent or in combination with a corticosteroid, has a high tole rability profile and achieves superior efficacy in preventing CINV compared with the other 5-HT<sub>3</sub> RAs (Aapro et al. <xref ref-type="bibr" rid="CR2">2006</xref>; Eisenberg et al. <xref ref-type="bibr" rid="CR15">2003</xref>; Gralla et al. <xref ref-type="bibr" rid="CR19">2003</xref>; Saito et al. <xref ref-type="bibr" rid="CR36">2009</xref>).</p><p>Preclinical data demonstrated that NEPA synergistically enhanced inhibition of the substance P response compared to either palonosetron or netupitant alone (Stathis et al. <xref ref-type="bibr" rid="CR40">2012</xref>). These data suggest that the NEPA combination represents an effective and convenient approach to prevent acute and delayed CINV with a single oral dose.</p><p>Cardiovascular disease represents one of the most common comorbidities in the growing population of cancer patients aged more than 65&#x000a0;years (Aapro et al. <xref ref-type="bibr" rid="CR1">2005</xref>). Cardiopathy can be preexisting or a consequence of the malignancy, and ECG changes can be an adverse event (AE) resulting from chemotherapy treatment. Several antineoplastic agents (especially anthracyclines) and some platinum compounds are associated with ECG alterations, including prolongation of the QT interval, development of ventricular late potentials, and various arrhythmias. It has been shown that the interaction of anthracyclines with the monoclonal antibody trastuzumab, which is quite common in breast cancer patients, can potentiate cardiotoxic effects (Bagnes et al. <xref ref-type="bibr" rid="CR7">2010</xref>). Cyclophosphamide treatment has been associated with 7% to 28% incidence of heart failure, while cisplatin has been associated with 8.5% of venous thromboembolism incidence (Vo and Nelson <xref ref-type="bibr" rid="CR42">2012</xref>). The use of 5-fluorouracil has been reported to be associated with ECG changes (eg, ST segment deviation and corrected QT interval [QTc] prolongation in nearly 68% of patients) and cardiotoxicity (eg, angina, supraventricular tachycardia, and myocardial infarction with an incidence of 1%&#x02013;18%) (Sorrentino et al. <xref ref-type="bibr" rid="CR38">2012</xref>). Cardiotoxicity has also been reported after administration of taxanes (eg, brady- and tachyarrhythmia and other cardiac disturbances) (Bagnes et al. <xref ref-type="bibr" rid="CR7">2010</xref>; Yeh and Bickford <xref ref-type="bibr" rid="CR44">2009</xref>). The incidence of bradycardia associated with paclitaxel treatment ranges from &#x0003c;0.1% to 31% and the incidence of heart failure associated with docetaxel treatment ranges from &#x0003c;2.3% to 8% (Yeh and Bickford <xref ref-type="bibr" rid="CR44">2009</xref>). Both paclitaxel (&#x0003c;1%&#x02013;5% incidence) and docetaxel (1.7% incidence) have been associated with myocardial ischaemia (Yeh and Bickford <xref ref-type="bibr" rid="CR44">2009</xref>).</p><p>Not only chemotherapeutic agents, but also newer targeted agents have been shown to lead to cardiotoxicity (Bagnes et al. <xref ref-type="bibr" rid="CR7">2010</xref>; Hedhli and Russell <xref ref-type="bibr" rid="CR23">2011</xref>). Multikinase-targeted drugs (eg, sorafenib, sunitinib, imatinib, and dasatinib) are associated with various cardiac effects, such as hypertension, congestive heart failure, and QTc prolongation (Bagnes et al. <xref ref-type="bibr" rid="CR7">2010</xref>; Hedhli and Russell <xref ref-type="bibr" rid="CR23">2011</xref>). The use of histone deacetylase inhibitors has also been associated with QTc prolongation (Bagnes et al. <xref ref-type="bibr" rid="CR7">2010</xref>; Hedhli and Russell <xref ref-type="bibr" rid="CR23">2011</xref>). Administration of anti-vascular endothelial growth factor agents (eg, bevacizumab and aflibercept) can lead to hypertension, arrhythmia, and thromboembolic effects, such as myocardial infarction (Bagnes et al. <xref ref-type="bibr" rid="CR7">2010</xref>; Hedhli and Russell <xref ref-type="bibr" rid="CR23">2011</xref>).</p><p>The current double-blind, randomised, parallel-group study evaluated whether the combined administration of different doses of netupitant&#x02009;+&#x02009;palonosetron prolongs the individually heart rate-corrected QT interval (QTcI) more than placebo. Safety and tolerability of the combination therapy, as well as pharmacokinetic (PK) data, were evaluated.</p></sec><sec id="Sec2" sec-type="methods"><title>Methods</title><sec id="Sec3"><title>Study design and treatment</title><p>This was a phase I, randomised, double-blind (except for the use of moxifloxacin), double-dummy, parallel-group, placebo- and open-label positively controlled study (EudraCT: 2007-004365-17). The study was approved by appropriate ethics committees and was conducted in accordance with the Declaration of Helsinki, the German Drug Law, and the German Good Clinical Practice decree. All subjects gave written informed consent to participate in the trial. The primary objective of this study was to assess whether the combined administration of different doses of netupitant&#x02009;+&#x02009;palonosetron prolongs QTcI more than placebo. Secondary objectives were to evaluate the safety and tolerability of NEPA combinations and assess the PK of netupitant, palonosetron, and their metabolites.</p><p>The trial design followed the provisions of ICH Guideline E14 for a &#x0201c;thorough QT/QTc study&#x0201d; (US Department of Health and Human Services <xref ref-type="bibr" rid="CR41">2005</xref>). The study consisted of an ambulant screening phase (days &#x02013;21 to &#x02013;3), a pre-check period (day &#x02013;2 and &#x02013;1), a treatment period (days 1&#x02013;3), and an ambulant final check 14 to 21&#x000a0;days after discharge from the study center on day 3. Subjects were hospitalised from the evening of day &#x02013;2 until day 3. Subjects were randomly assigned to one of the following single-dose treatment groups: placebo, 200&#x000a0;mg netupitant&#x02009;+&#x02009;0.50&#x000a0;mg palonosetron (NEPA<sub>200/0.5</sub>), 600&#x000a0;mg netupitant&#x02009;+&#x02009;1.50&#x000a0;mg palonosetron (NEPA<sub>600/1.5</sub>), and 400&#x000a0;mg moxifloxacin (Avelox&#x000ae;, Bayer Healthcare; positive control). A 24-hour baseline ECG was followed by a single dose of treatment on day 1, after which subjects had ECG and PK measurements up to 48&#x000a0;hours postdose.</p></sec><sec id="Sec4"><title>Subjects</title><p>Two hundred healthy subjects (at least 92 of each gender) aged 18 to 45&#x000a0;years were included if they had a body mass index of 19 to &#x0003c;29&#x000a0;kg/m<sup>2</sup>, were nonsmokers (or refrained from smoking or taking other nicotine-containing products for 3&#x000a0;months prior to dosing), and had normal blood pressure (55&#x02013;89/95&#x02013;149&#x000a0;mmHg) and pulse rate (45&#x02013;95 beats/minute). Subjects with any of the following were excluded: current use of oral contraceptives or hormones within 3&#x000a0;months prior to dosing; pregnant or breastfeeding; use of prescribed or over-the-counter medication within 14&#x000a0;days of dosing; any active physical disease (acute or chronic); gastrointestinal complaints within 7&#x000a0;days of dosing; febrile or infectious illness within 7&#x000a0;days of dosing; any cardiovascular condition; any abnormal ECG interval or changes in ECG that might interfere with measurement of QT interval; relevant drug hypersensitivity (specifically against moxifloxacin); known contraindication to NK<sub>1</sub> RAs, 5-HT<sub>3</sub> RAs, or fluoroquinolones; positive test for hepatitis B virus, hemoglobin C, or human immunodeficiency virus; or any other reason deemed unsuitable in the opinion of the investigator.</p></sec><sec id="Sec5"><title>Pharmacodynamics</title><p>ECGs were obtained using a continuous 12-lead digital Holter recorder (Mortara H-12; Milwaukee, WI) on day &#x02013;1 (baseline) and on days 1 and 2. ECGs to be used in the analysis were selected at the following predetermined time points: day &#x02013;1 at &#x02013;23, &#x02013;22, &#x02013;20, &#x02013;19, &#x02013;18, &#x02013;17, &#x02013;16, &#x02013;14, &#x02013;12, &#x02013;10, &#x02013;8, &#x02013;6, and &#x02013;0.5&#x000a0;hours; days 1 and 2 at 1, 2, 4, 5, 6, 7, 8, 10, 12, 14, 16, 18, 23.5, 30, 36, 42, and 47.5&#x000a0;hours. Four ECGs were obtained at each time point. Three kinds of QTc were calculated. The primary ECG endpoint was QTcI, calculated as QTcI&#x02009;=&#x02009;QT/(RR)<sup>slope</sup>, where the slope was determined for each subject by linear regression analysis on the baseline ECGs. Secondary ECG variables included frequency correction performed using the Fridericia formula (QTcF) and frequency correction performed using Bazett formula (QTcB). Additionally, the following parameters were evaluated: uncorrected QT interval, heart rate (HR), PR interval, QRS interval, and change in ECG morphologic patterns.</p></sec><sec id="Sec6"><title>Pharmacokinetics</title><p>The area under the plasma concentration-time curve data from administration until the last sampling point (AUC<sub>0-t</sub>), maximum plasma concentration (C<sub>max</sub>), and t<sub>max</sub> were determined for netupitant (and its metabolites M1, M2, and M3) and palonosetron (and its metabolites M4 and M9), if data permitted. AUC<sub>0-t</sub> was calculated by the linear trapezoidal formula, C<sub>max</sub> was defined as the highest observed plasma concentration of the measured concentration-time profile, and t<sub>max</sub> was set as the time after administration at which C<sub>max</sub> occurred.</p><p>A simultaneous, validated, internally standardised liquid chromatography-tandem mass spectrometry (LC-MS/MS) method with electrospray ionisation in the positive mode was used for the analysis of netupitant and its metabolites M1, M2, and M3 and palonosetron and its metabolites M4 and M9. The analytics methods used for determination of netupitant and palonosetron and their metabolites are validated and approved by the US Food and Drug Administration and European Medicines Agency guidelines and were performed accordingly.</p></sec><sec id="Sec7"><title>Safety and tolerability parameters</title><p>Safety and tolerability parameters included physical examination, vital signs, body temperature, body weight, ECG recording, and laboratory examinations (clinical chemistry, haematology, urinalysis, serology, drug screen and alcohol breath test, and pregnancy test). AEs were ascertained and rated by the investigators. Overall tolerability was assessed by the investigator at the end of the study.</p></sec><sec id="Sec8"><title>Statistics methods</title><p>Biometric and PK evaluation were carried out using SAS&#x000ae; (Version 9.1). Descriptive statistics were used to summarise demographic data and ECG variables at each time point. For the QTc analysis, 2-sided 90% confidence intervals (CIs) based on the intersection&#x02013;union test were calculated for each matched time (time-matched analysis). If the upper limit of the 2-sided 90% CI for the study treatment versus placebo did not exceed 10 milliseconds (ms) at any time point, it was concluded that this dose did not prolong the QTc interval to a clinically significant degree. To establish assay sensitivity, at least 1 time point with a mean difference of moxifloxacin and placebo &#x0003e;5&#x000a0;ms had to be observed.</p><p>In addition to the time-matched analysis, the time-averaged analysis was calculated. For each subject and for the ECG parameters QTc (I, B, F), HR, PR, QRS, and QT, the mean of all baseline ECGs was calculated as the time-averaged baseline value, and the mean of all postdose ECGs was calculated as the time-averaged postdose value. The time-averaged change from baseline was calculated from both values. The placebo-corrected time-averaged change from baseline was calculated by subtracting the mean placebo baseline-corrected values from the mean time-averaged change from baseline of the other treatment groups.</p><p>The PK/pharmacodynamics (PD) analysis explored the relationship between the placebo-adjusted QTcI change from baseline and plasma concentrations of netupitant and palonosetron. A linear mixed-effects modeling approach was adopted in which this PK/PD relationship was a fixed effect with subject included as a random effect (&#x00394;&#x00394;QTcI&#x02009;=&#x02009;&#x003b1;&#x02009;+&#x02009;&#x003b2;&#x02009;&#x02217;&#x02009;[plasma concentration]&#x02009;+&#x02009;&#x003b3;&#x02009;&#x02217;&#x02009;[subject effect]). This model was used to estimate the population slope and the standard error (SE) of the slope. A linear relationship was declared if the p-value of the slope was &#x0003c;0.05. The mean maximum effect (C<sub>max</sub>&#x02009;&#x02217;&#x02009;&#x003b2;) and the upper 1-sided 95% CI (C<sub>max</sub>&#x02009;&#x02217;&#x02009;&#x003b2;&#x02009;+&#x02009;[1.65&#x02009;&#x02217;&#x02009;SE &#x003b2;&#x02009;&#x02217;&#x02009;C<sub>max</sub>]) were calculated.</p><p>A sample size of 50 subjects per group was expected to provide at least 80% power to show for the comparison of netupitant/palonosetron to placebo that the upper limit of the 90% CI falls below 10&#x000a0;ms. The sample size was calculated based on an assumed standard deviation of 11&#x000a0;ms. The true difference between time-matched changes from baseline QTcI of netupitant/palonosetron and placebo groups was selected as 3&#x000a0;ms.</p></sec></sec><sec id="Sec9" sec-type="results"><title>Results</title><sec id="Sec10"><title>Disposition and baseline characteristics</title><p>Two hundred subjects (106 males and 94 females) were enrolled in the study. Five women withdrew consent and discontinued the study. Three of them withdrew their consent before treatment administration and were therefore not included in any analysis. One subject in the NEPA<sub>200/0.5</sub> group did not show netupitant plasma levels and was therefore excluded from the PD analyses. One hundred ninety-five subjects completed the study. The baseline characteristics of the study population were comparable between treatment groups and are shown in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1"><label>Table 1</label><caption><p>
<bold>Baseline characteristics</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Placebo (N&#x02009;=&#x02009;50)</th><th>NEPA
<sub>200/0.5</sub> (N&#x02009;=&#x02009;49)</th><th>NEPA
<sub>600/1.5</sub> (N&#x02009;=&#x02009;49)</th><th>Moxifloxacin (N&#x02009;=&#x02009;49)</th></tr></thead><tbody><tr><td>Age, years</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td>&#x02003;Mean (SD)</td><td align="center">34.7 (7.12)</td><td align="center">33.6 (6.86)</td><td align="center">32.8 (8.36)</td><td align="center">34.7 (7.98)</td></tr><tr><td>&#x02003;Min&#x02013;max</td><td align="center">19&#x02013;45</td><td align="center">21&#x02013;44</td><td align="center">19&#x02013;45</td><td align="center">19&#x02013;45</td></tr><tr><td>Gender, n (%)</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td>&#x02003;Male</td><td align="center">26 (52)</td><td align="center">27 (55)</td><td align="center">27 (55)</td><td align="center">26 (53)</td></tr><tr><td>&#x02003;Female</td><td align="center">24 (48)</td><td align="center">22 (45)</td><td align="center">22 (45)</td><td align="center">23 (47)</td></tr><tr><td>BMI, kg/m<sup>2</sup>
</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td>&#x02003;Mean (SD)</td><td align="center">24.45 (2.486)</td><td align="center">24.27 (2.608)</td><td align="center">24.51 (2.516)</td><td align="center">24.89 (2.674)</td></tr><tr><td>&#x02003;Min&#x02013;max</td><td align="center">19.0&#x02013;28.9</td><td align="center">19.2&#x02013;28.5</td><td align="center">19.4&#x02013;28.9</td><td align="center">19.4&#x02013;29.0</td></tr></tbody></table><table-wrap-foot><p>BMI, body mass index; SD, standard deviation.</p><p>NEPA<sub>200/0.5</sub>: 200&#x000a0;mg netupitant (50&#x000a0;mg&#x02009;+&#x02009;150&#x000a0;mg)&#x02009;+&#x02009;0.50&#x000a0;mg palonosetron (1&#x02009;&#x000d7;&#x02009;0.50&#x000a0;mg).</p><p>NEPA<sub>600/1.5</sub>: 600&#x000a0;mg netupitant (4&#x02009;&#x000d7;&#x02009;150&#x000a0;mg)&#x02009;+&#x02009;1.50&#x000a0;mg palonosetron (3&#x02009;&#x000d7;&#x02009;0.50&#x000a0;mg).</p><p>Percentages are based on N.</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec11"><title>Pharmacodynamics</title><p>One hundred ninety-six subjects were included in the PD analyses. Because heart rate inversely affects QT duration, the assessment of cardiac repolarisation was based on QTcI. The QTcI mean time-averaged placebo-corrected change from baseline for NEPA<sub>200/0.5</sub> and NEPA<sub>600/1.5</sub> was +4.7 and +3.6&#x000a0;ms, respectively (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). For QTcB, values were &#x02013;0.9 and &#x02013;0.5&#x000a0;ms for NEPA<sub>200/0.5</sub> and NEPA<sub>600/1.5</sub> groups, respectively. For the time-averaged analysis, the mean placebo-corrected change from baseline for heart rate was similar for the NEPA<sub>200/0.5</sub> and NEPA<sub>600/1.5</sub> groups (&#x02013;3.3 and &#x02013;3.0&#x000a0;bpm, respectively; Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). Mean placebo-corrected change from baseline for PR and QRS durations was similar for the NEPA<sub>200/0.5</sub> (PR: &#x02013;0.4&#x000a0;ms; QRS: 1.0&#x000a0;ms) and NEPA<sub>600/1.5</sub> (PR: 0.2&#x000a0;ms; QRS: 0.5&#x000a0;ms) groups, and was not considered clinically relevant (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>
<bold>Time-averaged analysis: mean changes from baseline</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Endpoint</th><th rowspan="2">Parameter</th><th>Placebo (N&#x02009;=&#x02009;50)</th><th colspan="2">NEPA
<sub>200/0.5</sub> (N&#x02009;=&#x02009;48)</th><th colspan="2">NEPA
<sub>600/1.5</sub> (N&#x02009;=&#x02009;49)</th><th colspan="2">Moxifloxacin (N&#x02009;=&#x02009;49)</th></tr><tr><th>Change from baseline</th><th>Change from baseline</th><th>Placebo-corrected change from baseline</th><th>Change from baseline</th><th>Placebo-corrected change from baseline</th><th>Change from baseline</th><th>Placebo-corrected change from baseline</th></tr></thead><tbody><tr><td>Primary</td><td align="center">QTcI, ms</td><td align="center">&#x02013;2.1</td><td align="center">2.6</td><td align="center">4.7</td><td align="center">1.5</td><td align="center">3.6</td><td align="center">6.3</td><td align="center">8.4</td></tr><tr><td/><td align="center">(Min;max)</td><td align="center">(&#x02212;8.3; 4.8)</td><td align="center">(&#x02212;5.8; 30.6)</td><td align="center"/><td align="center">(&#x02212;7.3; 14.3)</td><td align="center"/><td align="center">(&#x02212;2.6; 15.3)</td><td align="center"/></tr><tr><td>Secondary</td><td align="center">HR, bpm</td><td align="center">&#x02013;0.7</td><td align="center">&#x02013;4.0</td><td align="center">&#x02013;3.3</td><td align="center">&#x02013;3.7</td><td align="center">&#x02013;3.0</td><td align="center">&#x02013;0.4</td><td align="center">0.3</td></tr><tr><td/><td align="center">PR, ms</td><td align="center">1.1</td><td align="center">0.7</td><td align="center">&#x02013;0.4</td><td align="center">1.3</td><td align="center">0.2</td><td align="center">&#x02013;0.2</td><td align="center">&#x02013;1.3</td></tr><tr><td/><td align="center">QRS, ms</td><td align="center">&#x02013;0.3</td><td align="center">0.7</td><td align="center">1.0</td><td align="center">0.2</td><td align="center">0.5</td><td align="center">0.0</td><td align="center">0.3</td></tr><tr><td/><td align="center">QT, ms</td><td align="center">&#x02013;0.4</td><td align="center">9.3</td><td align="center">9.7</td><td align="center">8.6</td><td align="center">9.0</td><td align="center">6.9</td><td align="center">7.3</td></tr><tr><td/><td align="center">QTcF, ms</td><td align="center">&#x02013;2.1</td><td align="center">0.5</td><td align="center">2.6</td><td align="center">0.5</td><td align="center">2.6</td><td align="center">6.0</td><td align="center">8.1</td></tr><tr><td/><td align="center">QTcB, ms</td><td align="center">&#x02013;3.0</td><td align="center">&#x02013;3.9</td><td align="center">&#x02013;0.9</td><td align="center">&#x02013;3.5</td><td align="center">&#x02013;0.5</td><td align="center">5.5</td><td align="center">8.5</td></tr></tbody></table><table-wrap-foot><p>bpm, beats per minute; min, minimum; max, maximum; HR, heart rate; ms, milliseconds; QTcB, Bazett correction; QTcF, Fridericia correction; QTcI, individually heart rate-corrected QT interval.</p><p>NEPA<sub>200/0.5</sub>: 200&#x000a0;mg netupitant (50&#x000a0;mg&#x02009;+&#x02009;150&#x000a0;mg)&#x02009;+&#x02009;0.50&#x000a0;mg palonosetron (1&#x02009;&#x000d7;&#x02009;0.50&#x000a0;mg).</p><p>NEPA <sub>600/1.5</sub>: 600&#x000a0;mg netupitant (4&#x02009;&#x000d7;&#x02009;150&#x000a0;mg)&#x02009;+&#x02009;1.50&#x000a0;mg palonosetron (3&#x02009;&#x000d7;&#x02009;0.50&#x000a0;mg).</p></table-wrap-foot></table-wrap></p><p>These data showed no signs for an effect of different doses of netupitant&#x02009;+&#x02009;palonosetron on QTc (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). In the moxifloxacin-treated group, the placebo-corrected mean change from baseline for QTcI and QTcB values was +8.4 and +8.5&#x000a0;ms, respectively (expected 5&#x02013;10&#x000a0;ms), indicating assay sensitivity was reached (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). In the placebo group the QTcI and QTcB mean changes from baseline were &#x02013;2.1 and &#x02013;3.0&#x000a0;ms, respectively, showing that background QTc was controlled (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).</p><p>A time-matched analysis was conducted as recommended by ICH E14 with placebo- and baseline-corrected QTcI data for NEPA and moxifloxacin dose groups. The analysis for QTcI revealed that the moxifloxacin group met the assay sensitivity criteria with 12 time points above a mean of 5&#x000a0;ms (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>, Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>a). Results showed that the NEPA groups did not exceed the upper CI of 10&#x000a0;ms at any of the time points (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>, Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>a). Therefore, the combination of different doses of netupitant and palonosetron did not prolong the QTc interval to a clinically significant degree.<table-wrap id="Tab3"><label>Table 3</label><caption><p>
<bold>Time-matched analysis: placebo and baseline corrected QTcI data for NEPA and moxifloxacin dose groups</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Time, h</th><th colspan="2">NEPA
<sub>200/0.5</sub>
</th><th colspan="2">NEPA
<sub>600/1.5</sub>
</th><th colspan="2">Moxifloxacin</th></tr><tr><th>Estimate
<sup>1</sup>
</th><th>Upper bound
<sup>2</sup>
</th><th>Estimate
<sup>1</sup>
</th><th>Upper bound
<sup>2</sup>
</th><th>Estimate
<sup>1</sup>
</th><th>Upper bound
<sup>2</sup>
</th></tr></thead><tbody><tr><td>1</td><td align="center">3.2</td><td align="center">5.2</td><td align="center">3.5</td><td align="center">5.3</td><td align="center">12.2</td><td align="center">15.1</td></tr><tr><td>2</td><td align="center">3.8</td><td align="center">5.9</td><td align="center">1.0</td><td align="center">2.8</td><td align="center">12.7</td><td align="center">15.6</td></tr><tr><td>4</td><td align="center">5.5</td><td align="center">7.6</td><td align="center">1.7</td><td align="center">3.5</td><td align="center">13.7</td><td align="center">16.6</td></tr><tr><td>5</td><td align="center">4.8</td><td align="center">6.9</td><td align="center">2.5</td><td align="center">4.3</td><td align="center">12.2</td><td align="center">15.1</td></tr><tr><td>6</td><td align="center">3.5</td><td align="center">5.6</td><td align="center">4.3</td><td align="center">6.1</td><td align="center">9.7</td><td align="center">12.6</td></tr><tr><td>7</td><td align="center">4.5</td><td align="center">6.5</td><td align="center">4.1</td><td align="center">5.9</td><td align="center">10.5</td><td align="center">13.4</td></tr><tr><td>8</td><td align="center">5.3</td><td align="center">7.4</td><td align="center">4.3</td><td align="center">6.1</td><td align="center">9.6</td><td align="center">12.6</td></tr><tr><td>10</td><td align="center">6.1</td><td align="center">8.1</td><td align="center">5.2</td><td align="center">7.0</td><td align="center">10.8</td><td align="center">13.7</td></tr><tr><td>12</td><td align="center">5.7</td><td align="center">7.8</td><td align="center">3.6</td><td align="center">5.4</td><td align="center">9.2</td><td align="center">12.1</td></tr><tr><td>14</td><td align="center">6.7</td><td align="center">8.7</td><td align="center">4.9</td><td align="center">6.7</td><td align="center">7.5</td><td align="center">10.4</td></tr><tr><td>16</td><td align="center">5.5</td><td align="center">7.6</td><td align="center">7.0</td><td align="center">8.8</td><td align="center">8.0</td><td align="center">10.9</td></tr><tr><td>18</td><td align="center">6.0</td><td align="center">8.1</td><td align="center">5.3</td><td align="center">7.1</td><td align="center">7.1</td><td align="center">10.0</td></tr><tr><td>23.5</td><td align="center">1.7</td><td align="center">3.7</td><td align="center">3.3</td><td align="center">5.1</td><td align="center">4.7</td><td align="center">7.6</td></tr><tr><td>30</td><td align="center">4.9</td><td align="center">7.0</td><td align="center">4.4</td><td align="center">6.2</td><td align="center">5.2</td><td align="center">8.1</td></tr><tr><td>36</td><td align="center">3.9</td><td align="center">6.0</td><td align="center">3.2</td><td align="center">5.0</td><td align="center">3.8</td><td align="center">6.7</td></tr><tr><td>42</td><td align="center">4.3</td><td align="center">6.4</td><td align="center">0.8</td><td align="center">2.6</td><td align="center">3.0</td><td align="center">5.9</td></tr><tr><td>47.5</td><td align="center">1.8</td><td align="center">3.8</td><td align="center">0.6</td><td align="center">2.4</td><td align="center">2.3</td><td align="center">5.3</td></tr><tr><td>Time average</td><td align="center">4.6</td><td align="center">5.7</td><td align="center">3.4</td><td align="center">4.5</td><td align="center">8.4</td><td align="center">9.5</td></tr></tbody></table><table-wrap-foot><p>ANOVA, analysis of variance; QTcI, individually heart rate-corrected QT interval.</p><p>NEPA<sub>200/0.5</sub>: 200&#x000a0;mg netupitant (50&#x000a0;mg&#x02009;+&#x02009;150&#x000a0;mg)&#x02009;+&#x02009;0.50&#x000a0;mg palonosetron (1&#x02009;&#x000d7;&#x02009;0.50&#x000a0;mg).</p><p>NEPA<sub>600/1.5</sub>: 600&#x000a0;mg netupitant (4&#x02009;&#x000d7;&#x02009;150&#x000a0;mg)&#x02009;+&#x02009;1.50&#x000a0;mg palonosetron (3&#x02009;&#x000d7;&#x02009;0.50&#x000a0;mg).</p><p>
<sup>1</sup>Mixed-model ANOVA is fit for placebo-corrected change from baseline and includes terms for treatment, gender, time, and a time-by-treatment interaction.</p><p>
<sup>2</sup>Upper bound, upper 1-sided 95% ANOVA model-based confidence limit.</p></table-wrap-foot></table-wrap><fig id="Fig1"><label>Figure 1</label><caption><p>
<bold>Placebo- and baseline-corrected change in QTcI. (a)</bold> Placebo- and baseline-corrected change in QTcI for each time point in each treatment group. <bold>(b)</bold> Pharmacokinetic/pharmacodynamics relationship: placebo- and baseline-corrected change in QTcI versus netupitant plasma concentrations and <bold>(c)</bold> versus palonosetron plasma concentrations.</p></caption><graphic xlink:href="40064_2014_1088_Fig1_HTML" id="d30e1768"/></fig></p><p>No significant gender effect was observed. Morphologic changes were not considered clinically significant in any dose group and there were no imbalances in the NEPA<sub>200/0.5</sub> and NEPA<sub>600/1.5</sub> groups.</p></sec><sec id="Sec12"><title>Pharmacokinetics</title><p>PK parameters were assessed for netupitant and its metabolites M1, M2, and M3 and palonosetron and its metabolites M9 and M4.</p><p>A dose-proportional increase of the geometric mean AUC<sub>0-t</sub> was observed for netupitant (4079&#x000a0;h&#x02009;&#x02217;&#x02009;&#x003bc;g/L at 200&#x000a0;mg to 12213&#x000a0;h&#x02009;&#x02217;&#x02009;&#x003bc;g/L at 600&#x000a0;mg) and palonosetron (22641&#x000a0;h&#x02009;&#x02217;&#x02009;ng/L at 0.5&#x000a0;mg to 67918&#x000a0;h&#x02009;&#x02217;&#x02009;ng/L at 1.5&#x000a0;mg). Similarly, C<sub>max</sub> increased with dose for both netupitant (219&#x000a0;&#x003bc;g/L to 648&#x000a0;&#x003bc;g/L) and palonosetron (822&#x000a0;ng/L to 2588&#x000a0;ng/L; Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>). The intersubject PK variability was higher for netupitant than for palonosetron. The intersubject variability of netupitant for AUC<sub>0-t</sub> and C<sub>max</sub> was 42% and 48% at 200&#x000a0;mg, and 47% and 56% at 600&#x000a0;mg. For palonosetron, the intersubject variability for AUC<sub>0-t</sub> and C<sub>max</sub> varied from 20% to 29%. The pharmacokinetics of netupitant and palonosetron, including their metabolites, confirm that the ECG time points were adequately chosen, since the C<sub>max</sub> of all analytes lie within the ECG measurement time points.<table-wrap id="Tab4"><label>Table 4</label><caption><p>
<bold>Descriptive statistics of PK parameters for netupitant and palonosetron</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Netupitant</th><th>AUC
<sub>0-t</sub> (h&#x02009;&#x02217;&#x02009;&#x003bc;g/L) Geo. Mean (Geo. SD)</th><th>C
<sub>max</sub> (&#x003bc;g/L) Geo. Mean (Geo. SD)</th><th>t
<sub>max</sub> (h) Geo. Mean (Geo. SD)</th></tr></thead><tbody><tr><td>NEPA<sub>200/0.5</sub>
</td><td align="center"/><td align="center"/><td align="center"/></tr><tr><td>&#x02003;Parent</td><td align="center">4079 (1.712)</td><td align="center">218.7 (1.833)</td><td align="center">5.218 (1.589)</td></tr><tr><td>&#x02003;M1</td><td align="center">832.5 (1.719)</td><td align="center">23.55 (1.594)</td><td align="center">14.54 (1.668)</td></tr><tr><td>&#x02003;M2</td><td align="center">827.3 (1.722)</td><td align="center">96.94 (1.842)</td><td align="center">3.580 (1.342)</td></tr><tr><td>&#x02003;M3</td><td align="center">1348 (1.642)</td><td align="center">46.73 (1.559)</td><td align="center">10.70 (1.490)</td></tr><tr><td>NEPA<sub>600/1.5</sub>
</td><td align="center"/><td align="center"/><td align="center"/></tr><tr><td>&#x02003;Parent</td><td align="center">12213 (1.925)</td><td align="center">647.7 (2.205)</td><td align="center">6.104 (1.474)</td></tr><tr><td>&#x02003;M1</td><td align="center">2007 (1.766)</td><td align="center">53.71 (1.763)</td><td align="center">17.82 (1.948)</td></tr><tr><td>&#x02003;M2</td><td align="center">2155 (1.908)</td><td align="center">227.8 (2.024)</td><td align="center">4.131 (1.208)</td></tr><tr><td>&#x02003;M3</td><td align="center">2981 (1.707)</td><td align="center">101.5 (1.822)</td><td align="center">11.51 (1.555)</td></tr><tr><td>
<bold>Palonosetron</bold>
</td><td align="center">
<bold>AUC</bold>
<sub><bold>0-t</bold></sub>
<bold>(h</bold>&#x02009;&#x02217;&#x02009;<bold>ng/L) Geo. Mean (Geo. SD)</bold>
</td><td align="center">
<bold>C</bold>
<sub><bold>max</bold></sub>
<bold>(ng/L) Geo. Mean (Geo. SD)</bold>
</td><td align="center">
<bold>t</bold>
<sub><bold>max</bold></sub>
<bold>(h) Geo. Mean (Geo. SD)</bold>
</td></tr><tr><td>NEPA<sub>200/0.5</sub>
</td><td align="center"/><td align="center"/><td align="center"/></tr><tr><td>&#x02003;Parent</td><td align="center">22641 (1.241)</td><td align="center">821.6 (1.277)</td><td align="center">5.464 (1.437)</td></tr><tr><td>&#x02003;M4</td><td align="center">541.7 (2.916)</td><td align="center">72.72 (1.379)</td><td align="center">3.675 (1.764)</td></tr><tr><td>&#x02003;M9</td><td align="center">416.2 (2.158)</td><td align="center">105.0 (1.383)</td><td align="center">1.746 (1.348)</td></tr><tr><td>NEPA<sub>600/1.5</sub>
</td><td align="center"/><td align="center"/><td align="center"/></tr><tr><td>&#x02003;Parent</td><td align="center">67918 (1.210)</td><td align="center">2588 (1.239)</td><td align="center">4.229 (1.693)</td></tr><tr><td>&#x02003;M4</td><td align="center">5571 (1.348)</td><td align="center">231.0 (1.330)</td><td align="center">3.388 (1.734)</td></tr><tr><td>&#x02003;M9</td><td align="center">3973 (1.468)</td><td align="center">348.9 (1.313)</td><td align="center">1.781 (1.535)</td></tr></tbody></table><table-wrap-foot><p>AUC<sub>0-t</sub>, area under the plasma concentration-time curve data from administration until the last sampling point; C<sub>max</sub>, maximum plasma concentration; Geo., geometric; PK, pharmacokinetic; SD, standard deviation; t<sub>max</sub>, time to C<sub>max</sub>.</p><p>NEPA<sub>200/0.5</sub>: 200&#x000a0;mg netupitant (50&#x000a0;mg&#x02009;+&#x02009;150&#x000a0;mg)&#x02009;+&#x02009;0.50&#x000a0;mg palonosetron (1&#x02009;&#x000d7;&#x02009;0.50&#x000a0;mg).</p><p>NEPA<sub>600/1.5</sub>: 600&#x000a0;mg netupitant (4&#x02009;&#x000d7;&#x02009;150&#x000a0;mg)&#x02009;+&#x02009;1.50&#x000a0;mg palonosetron (3&#x02009;&#x000d7;&#x02009;0.50&#x000a0;mg).</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec13"><title>Pharmacodynamics/pharmacokinetics relationship</title><p>The relationship between placebo- and baseline-corrected QTcI duration and plasma concentration from paired samples taken in both dose groups for netupitant (Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>b) and palonosetron (Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>c) was evaluated. There were no indications that exposure to netupitant or palonosetron (parent or M1, M2, or M3 metabolites for netupitant; M9 or M4 metabolite for palonosetron) induced changes in QTc parameters. All estimated slopes were close to 0 and no upper CI approached 10&#x000a0;ms.</p></sec><sec id="Sec14"><title>Safety and tolerability</title><p>During the study, a total of 60 AEs were reported by 49 subjects. AEs were reported for 12 (24.0%) subjects in the placebo, 10 (20.4%) in the NEPA<sub>200/0.5</sub>, 17 (34.7%) in the NEPA<sub>600/1.5</sub>, and 10 (20.4%) in the moxifloxacin groups. Possibly or probably treatment-related AEs (TRAEs) were reported for 9 (18.0%) placebo subjects and 8 (16.3%), 10 (20.4%), and 8 (16.3%) subjects in the NEPA<sub>200/0.5</sub>, NEPA<sub>600/1.5</sub>, and moxifloxacin groups, respectively (Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref>). The incidence of TRAEs in the NEPA<sub>200/0.5</sub> group was comparable to that of the placebo and moxifloxacin groups, although the frequency of TRAEs was slightly higher with NEPA<sub>600/1.5</sub>. With NEPA<sub>200/0.5</sub> treatment, most commonly reported TRAEs were constipation (3 subjects), followed by upper abdominal pain (2 subjects), and headache (2 subjects). In the NEPA<sub>600/1.5</sub> group, headache (5 subjects) was most commonly reported, followed by constipation (2 subjects). Subjects treated with moxifloxacin reported mainly dizziness (3 subjects) and headache (2 subjects).<table-wrap id="Tab5"><label>Table 5</label><caption><p>
<bold>Possibly or probably drug-related adverse events</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Adverse event</th><th>Placebo</th><th>NEPA
<sub>200/0.5</sub>
</th><th>NEPA
<sub>600/1.5</sub>
</th><th>Moxifloxacin</th></tr><tr><th>Number of subjects (%)</th><th>(N&#x02009;=&#x02009;50)</th><th>(N&#x02009;=&#x02009;49)</th><th>(N&#x02009;=&#x02009;49)</th><th>(N&#x02009;=&#x02009;49)</th></tr></thead><tbody><tr><td>Cardiac disorders</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td>&#x02003;Palpitations</td><td align="center">0</td><td align="center">0</td><td align="center">1 (2.0)</td><td align="center">0</td></tr><tr><td>Gastrointestinal disorders</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td>&#x02003;Abdominal pain upper</td><td align="center">0</td><td align="center">2 (4.1)</td><td align="center">0</td><td align="center">0</td></tr><tr><td>&#x02003;Constipation</td><td align="center">0</td><td align="center">3 (6.1)</td><td align="center">2 (4.1)</td><td align="center">0</td></tr><tr><td>&#x02003;Dry mouth</td><td align="center">1 (2.0)</td><td align="center">0</td><td align="center">0</td><td align="center">0</td></tr><tr><td>&#x02003;Dyspepsia</td><td align="center">1 (2.0)</td><td align="center">0</td><td align="center">0</td><td align="center">0</td></tr><tr><td>&#x02003;Flatulence</td><td align="center">1 (2.0)</td><td align="center">0</td><td align="center">0</td><td align="center">0</td></tr><tr><td>&#x02003;Nausea</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">1 (2.0)</td></tr><tr><td>General disorders and administration-site conditions</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td>&#x02003;Fatigue</td><td align="center">0</td><td align="center">1 (2.0)</td><td align="center">0</td><td align="center">1 (2.0)</td></tr><tr><td>&#x02003;Thirst</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">1 (2.0)</td></tr><tr><td>Musculoskeletal and connective tissue disorders</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td>&#x02003;Muscle twitching</td><td align="center">1 (2.0)</td><td align="center">0</td><td align="center">0</td><td align="center">0</td></tr><tr><td>&#x02003;Pain in extremity</td><td align="center">0</td><td align="center">0</td><td align="center">1 (2.0)</td><td align="center">0</td></tr><tr><td>&#x02003;Sensation of heaviness</td><td align="center">1 (2.0)</td><td align="center">0</td><td align="center">0</td><td align="center">0</td></tr><tr><td>Nervous system disorders</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td>&#x02003;Dizziness</td><td align="center">1 (2.0)</td><td align="center">0</td><td align="center">1 (2.0)</td><td align="center">3 (6.1)</td></tr><tr><td>&#x02003;Headache</td><td align="center">5 (10.0)</td><td align="center">2 (4.1)</td><td align="center">5 (10.2)</td><td align="center">2 (4.1)</td></tr><tr><td>&#x02003;Somnolence</td><td align="center">0</td><td align="center">0</td><td align="center">1 (2.0)</td><td align="center">0</td></tr><tr><td>Psychiatric disorders</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td>&#x02003;Anxiety</td><td align="center">0</td><td align="center">0</td><td align="center">1 (2.0)</td><td align="center">0</td></tr><tr><td>&#x02003;Euphoric mood</td><td align="center">0</td><td align="center">0</td><td align="center">1 (2.0)</td><td align="center">0</td></tr><tr><td>Total</td><td align="center">9 (18.0)</td><td align="center">8 (16.3)</td><td align="center">10 (20.4)</td><td align="center">8 (16.3)</td></tr></tbody></table><table-wrap-foot><p>NEPA<sub>200/0.5</sub>: 200&#x000a0;mg netupitant (50&#x000a0;mg&#x02009;+&#x02009;150&#x000a0;mg)&#x02009;+&#x02009;0.50&#x000a0;mg palonosetron (1&#x02009;&#x000d7;&#x02009;0.50&#x000a0;mg).</p><p>NEPA<sub>600/1.5</sub>: 600&#x000a0;mg netupitant (4&#x02009;&#x000d7;&#x02009;150&#x000a0;mg)&#x02009;+&#x02009;1.50&#x000a0;mg palonosetron (3&#x02009;&#x000d7;&#x02009;0.50&#x000a0;mg).</p><p>Percentages are based on N.</p></table-wrap-foot></table-wrap></p><p>No deaths occurred during the study. One subject had a serious AE (injury) caused by a staircase accident and recovered by the end of the study. The investigator assessed the event as unlikely related to study drug. No clinically significant laboratory changes were observed and there were no AEs associated with laboratory changes. No abnormalities were detected in vital signs or ECG. The overall tolerability was assessed as good in 193 subjects and as satisfactory in 4 subjects.</p></sec></sec><sec id="Sec15" sec-type="discussion"><title>Discussion</title><p>NEPA is an oral fixed-dose combination of netupitant 300&#x000a0;mg and palonosetron 0.5&#x000a0;mg targeting dual antiemetic pathways mediated by serotonin and substance P with a single administration on the day of chemotherapy. Since the incidence of cancer patients with cardiovascular-related diseases is growing, especially in the elderly population, the cardiac safety profile of drugs used for supportive care should be investigated.</p><p>As recommended by international antiemetic guidelines, especially in patients undergoing highly emetogenic chemotherapy, an NK<sub>1</sub> RA, a 5-HT<sub>3</sub> RA, and a corticosteroid are commonly coadministered to prevent CINV (Basch et al. <xref ref-type="bibr" rid="CR8">2011</xref>; Gralla et al. <xref ref-type="bibr" rid="CR20">2013</xref>; Roila et al. <xref ref-type="bibr" rid="CR32">2010</xref>; National Comprehensive Cancer Network <xref ref-type="bibr" rid="CR30">2013</xref>). Aprepitant and its prodrug fosaprepitant are the only NK<sub>1</sub> RAs currently available and used in clinical practice. A recent study investigating the cardiovascular safety of 200&#x000a0;mg fosaprepitant reported no clinically relevant effect on QTc interval at any time after infusion (including aprepitant t<sub>max</sub>) (Marbury et al. <xref ref-type="bibr" rid="CR28">2009</xref>; Emend (aprepitant) Prescribing Information <xref ref-type="bibr" rid="CR16">2006</xref>). The cardiovascular safety of another NK<sub>1</sub> RA whose development was recently interrupted, casopitant, was evaluated and similarly showed no evidence of QTc prolongation after a 3-day oral regimen (Johnson et al. <xref ref-type="bibr" rid="CR26">2010</xref>).</p><p>Although 5-HT<sub>3</sub> RAs such as dolasetron, ondansetron, and granisetron are perceived as safe by the medical community, cardiovascular issues have been reported. Ondansetron 4&#x000a0;mg has been associated with a statistically significant increased prolongation of QTc at various time points following administration in healthy subjects or surgical patients without additional risk factors for QTc prolongation (Charbit et al. <xref ref-type="bibr" rid="CR11">2005</xref>, <xref ref-type="bibr" rid="CR12">2008</xref>; Benedict et al. <xref ref-type="bibr" rid="CR9">1996</xref>; Zofran (ondansetron hydrochloride) Prescribing Information <xref ref-type="bibr" rid="CR45">2011</xref>). Although an adequate QT assessment was not conducted, QT prolongation has been associated with the use of granisetron, as shown in a study by Alidoosti et al. reporting prolongation of PR and QTc, and a decrease in HR in cancer patients (Alidoosti et al. <xref ref-type="bibr" rid="CR5">2009</xref>; Kytril (granisetron hydrochloride) Prescribing Information <xref ref-type="bibr" rid="CR27">2011</xref>). Dolasetron treatment resulted in dose-related increases in HR, PR intervals, and QRS intervals and a statistically significant increase in QTc interval (Benedict et al. <xref ref-type="bibr" rid="CR9">1996</xref>). Based on clinical evidence, dolasetron and the highest dose of ondansetron (32&#x000a0;mg) are no longer indicated for CINV prevention due to cardiovascular safety concerns. Contrary to these findings, recent studies, including a formal ICH E14 thorough QT trial, have reported that palonosetron does not prolong the QT interval and does not cause any significant acute change in repolarisation (QTc, corrected QT dispersion [QTcd]) or transmural dispersion indices (TpTe, TpTed, and TpTe/QT) (Dogan et al. <xref ref-type="bibr" rid="CR14">2012</xref>; Gonullu et al. <xref ref-type="bibr" rid="CR18">2012</xref>; Morganroth et al. <xref ref-type="bibr" rid="CR29">2007</xref>). The thorough QT/QTc (ICH E14) study in healthy subjects also demonstrated that palonosetron has no effect on the QT interval (QT/QTc) over the 0.25- to 2.25-mg range of exposure (Morganroth et al. <xref ref-type="bibr" rid="CR29">2007</xref>; Aloxi (palonosetron hydrochloride) Prescribing Information <xref ref-type="bibr" rid="CR6">2009</xref>). Yavas et al. demonstrated no acute effects of palonosetron on heart rate or blood pressure (Yavas et al. <xref ref-type="bibr" rid="CR43">2012</xref>).</p><p>This thorough ECG trial enrolled 200 healthy subjects to assess the impact of different doses of netupitant&#x02009;+&#x02009;palonosetron on cardiac repolarisation. The supratherapeutic dose of NEPA (NEPA<sub>600/1.5</sub>) was used to mimic exposure in healthy subjects that may occur in the target population under the worst circumstances (eg, concomitant liver disease, presence of heart disease, taking more than the prescribed clinical dose, etc.).</p><p>The present data demonstrate that different doses of NEPA have no significant effects on QTcl, HR, PR interval duration, QRS interval duration, or cardiac morphology compared with placebo. The validity of this trial was demonstrated by the fact that the moxifloxacin-positive control group showed the expected change in QTc duration to establish assay sensitivity. The placebo group&#x02019;s change from baseline was within 3.0&#x000a0;ms, indicating that spontaneous factors for QTc change are well controlled. A dose-proportional increase in AUC<sub>0-t</sub> and C<sub>max</sub> was observed for both netupitant and palonosetron. Administration of different doses of NEPA was safe and well tolerated in healthy subjects. Most commonly reported TRAEs with NEPA groups were constipation, abdominal pain, and headache. Although TRAEs were slightly more frequent with NEPA<sub>600/1.5</sub>, the dose combination was safe with an acceptable tolerability profile.</p><p>This trial was performed in healthy subjects (18&#x02013;45 years) to eliminate variables that are known to change ECG parameters, such as concomitant drugs and diseases. This study did not assess the cardiac safety of NEPA in cancer patients. However, a phase III study testing NEPA in cancer patients (without any serious cardiovascular disease history or predisposition to cardiac conduction abnormalities) receiving chemotherapy showed that there were no cardiac safety concerns for NEPA based on cardiac AEs and ECGs (Hesketh et al. <xref ref-type="bibr" rid="CR25">2014</xref>; Aapro et al. <xref ref-type="bibr" rid="CR4">2014</xref>; Gralla et al. <xref ref-type="bibr" rid="CR21">2014</xref>). Therefore, both in cancer patients and in healthy volunteers NEPA did not show any increased risk in cardiac safety profile.</p><p>In conclusion, in this thorough QT trial, different NEPA combinations showed no ECG effects, which should predict a lack of cardiac safety concerns in clinical practice. Treatments were well tolerated.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-list><def-item><term>5-HT</term><def><p>5-hydroxytryptamine</p></def></def-item><def-item><term>AE</term><def><p>Adverse event</p></def></def-item><def-item><term>AUC<sub>0-t</sub></term><def><p>Area under the plasma concentration-time curve from administration until the last sampling point</p></def></def-item><def-item><term>CINV</term><def><p>Chemotherapy-induced nausea and vomiting</p></def></def-item><def-item><term>CIs</term><def><p>Confidence intervals</p></def></def-item><def-item><term>C<sub>max</sub></term><def><p>Maximum plasma concentration</p></def></def-item><def-item><term>C<sub>max</sub>&#x02009;&#x02217;&#x02009;&#x003b2;</term><def><p>Mean maximum effect</p></def></def-item><def-item><term>HR</term><def><p>Heart rate</p></def></def-item><def-item><term>LC-MS/MS</term><def><p>Liquid chromatography-tandem mass spectrometry</p></def></def-item><def-item><term>NEPA</term><def><p>Netupitant and palonosetron</p></def></def-item><def-item><term>NEPA<sub>200/0.5</sub></term><def><p>200&#x000a0;mg netupitant&#x02009;+&#x02009;0.5&#x000a0;mg palonosetron</p></def></def-item><def-item><term>NEPA<sub>600/1.5</sub></term><def><p>600&#x000a0;mg netupitant&#x02009;+&#x02009;1.5&#x000a0;mg palonosetron</p></def></def-item><def-item><term>NK<sub>1</sub></term><def><p>Neurokinin 1</p></def></def-item><def-item><term>PD</term><def><p>Pharmacodynamics</p></def></def-item><def-item><term>PK</term><def><p>Pharmacokinetic</p></def></def-item><def-item><term>QTc</term><def><p>Corrected QT interval</p></def></def-item><def-item><term>QTcB</term><def><p>Frequency correction performed using Bazett formula</p></def></def-item><def-item><term>QTcd</term><def><p>Corrected QT dispersion</p></def></def-item><def-item><term>QTcF</term><def><p>Frequency correction performed using Fridericia formula</p></def></def-item><def-item><term>QTcI</term><def><p>Individually heart rate-corrected QT interval</p></def></def-item><def-item><term>RA</term><def><p>Receptor antagonist</p></def></def-item><def-item><term>SE</term><def><p>Standard error</p></def></def-item><def-item><term>t<sub>max</sub></term><def><p>Maximum plasma concentration</p></def></def-item><def-item><term>TRAEs</term><def><p>Treatment-related adverse events.</p></def></def-item></def-list></def-list></glossary><fn-group><fn><p><bold>Competing interests</bold></p><p>The authors have full control of all primary data and they agree to allow the journal to review their data if requested. Dr Spinelli and Dr Moresino are employees of Helsinn Healthcare SA, Lugano, Switzerland. Dr Baumann, Dr Timmer, and Dr Schultz were employees of CRS Clinical Research Services Mannheim, the CRO that conducted the study. They received a regular salary by the CRO which, in turn, has received a budget for the study conduct. None of the authors have further conflicts of interests related to the study to declare.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>TS: conception and design of the study, acquisition of data, analysis and interpretation of data, drafting and revising of the manuscript. CM: conception and design of the study, acquisition of data, analysis and interpretation of data, drafting and revising of the manuscript. SB: conception and design of the study, acquisition of data, analysis and interpretation of data, drafting and revising of the manuscript. WT: conception and design of the study, acquisition of data, analysis and interpretation of data, drafting and revising of the manuscript. AS: conception and design of the study, acquisition of data, analysis and interpretation of data, drafting and revising of the manuscript. All authors read and approved the final manuscript.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors are indebted to Joel Morganroth, MD, from eResearch Technology, Philadelphia, Pennsylvania, USA, for his contribution to the study design, data analysis, and manuscript preparation. In addition, the authors would like to thank Silvia Olivari Tilola and Silvia Sebastiani from Helsinn Healthcare SA, Lugano, Switzerland, as well as Jennifer Vanden Burgt, pharmaceutical consultant, and Norman Nagle from EISAI, New Jersey, USA, for critically reviewing the manuscript. The trial was sponsored by Helsinn Healthcare SA, Lugano, Switzerland. Editorial and medical writing assistance was provided by Margot Eggermont, PhD, and Sandra Mendes, PhD, CMPP, both from TRM Oncology, The Hague, The Netherlands, and funded by Helsinn Healthcare SA, Lugano, Switzerland.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aapro</surname><given-names>MS</given-names></name><name><surname>Macciocchi</surname><given-names>A</given-names></name><name><surname>Gridelli</surname><given-names>C</given-names></name></person-group><article-title>Palonosetron improves prevention of chemotherapy-induced nausea and vomiting in elderly patients</article-title><source>J Support Oncol</source><year>2005</year><volume>3</volume><issue>5</issue><fpage>369</fpage><lpage>374</lpage><pub-id pub-id-type="pmid">16218261</pub-id></element-citation></ref><ref id="CR2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aapro</surname><given-names>MS</given-names></name><name><surname>Grunberg</surname><given-names>SM</given-names></name><name><surname>Manikhas</surname><given-names>GM</given-names></name><name><surname>Olivares</surname><given-names>G</given-names></name><name><surname>Suarez</surname><given-names>T</given-names></name><name><surname>Tjulandin</surname><given-names>SA</given-names></name><name><surname>Bertoli</surname><given-names>LF</given-names></name><name><surname>Yunus</surname><given-names>F</given-names></name><name><surname>Morrica</surname><given-names>B</given-names></name><name><surname>Lordick</surname><given-names>F</given-names></name><name><surname>Macciocchi</surname><given-names>A</given-names></name></person-group><article-title>A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy</article-title><source>Ann Oncol</source><year>2006</year><volume>17</volume><issue>9</issue><fpage>1441</fpage><lpage>1449</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdl137</pub-id><pub-id pub-id-type="pmid">16766588</pub-id></element-citation></ref><ref id="CR3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aapro</surname><given-names>M</given-names></name><name><surname>Molassiotis</surname><given-names>A</given-names></name><name><surname>Dicato</surname><given-names>M</given-names></name><name><surname>Pel&#x000e1;ez</surname><given-names>I</given-names></name><name><surname>Rodr&#x000ed;guez-Lescure</surname><given-names>&#x000c1;</given-names></name><name><surname>Pastorelli</surname><given-names>D</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Burke</surname><given-names>T</given-names></name><name><surname>Gu</surname><given-names>A</given-names></name><name><surname>Gascon</surname><given-names>P</given-names></name><name><surname>Roila</surname><given-names>F</given-names></name><collab>PEER investigators</collab></person-group><article-title>The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER)</article-title><source>Ann Oncol</source><year>2012</year><volume>23</volume><issue>8</issue><fpage>1986</fpage><lpage>1992</lpage><pub-id pub-id-type="doi">10.1093/annonc/mds021</pub-id><pub-id pub-id-type="pmid">22396444</pub-id></element-citation></ref><ref id="CR4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aapro</surname><given-names>M</given-names></name><name><surname>Rugo</surname><given-names>H</given-names></name><name><surname>Rossi</surname><given-names>G</given-names></name><name><surname>Rizzi</surname><given-names>G</given-names></name><name><surname>Borroni</surname><given-names>ME</given-names></name><name><surname>Bondarenko</surname><given-names>I</given-names></name><name><surname>Sarosiek</surname><given-names>T</given-names></name><name><surname>Oprean</surname><given-names>C</given-names></name><name><surname>Cardona-Huerta</surname><given-names>S</given-names></name><name><surname>Lorusso</surname><given-names>V</given-names></name><name><surname>Karthaus</surname><given-names>M</given-names></name><name><surname>Schwartzberg</surname><given-names>L</given-names></name><name><surname>Grunberg</surname><given-names>S</given-names></name></person-group><article-title>A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy</article-title><source>Ann Oncol</source><year>2014</year><volume>25</volume><issue>7</issue><fpage>1328</fpage><lpage>1333</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdu101</pub-id><pub-id pub-id-type="pmid">24603643</pub-id></element-citation></ref><ref id="CR5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alidoosti</surname><given-names>A</given-names></name><name><surname>Taslimi</surname><given-names>F</given-names></name><name><surname>Ameri</surname><given-names>A</given-names></name><name><surname>Sheibani</surname><given-names>KM</given-names></name><name><surname>Miri</surname><given-names>R</given-names></name><name><surname>Yavari</surname><given-names>P</given-names></name></person-group><article-title>Electrocardiographic changes after granisetron administration for chemotherapy induced nausea and vomiting</article-title><source>Acta Medica Iranica</source><year>2009</year><volume>47</volume><issue>4</issue><fpage>289</fpage><lpage>292</lpage></element-citation></ref><ref id="CR6"><mixed-citation publication-type="other">Aloxi (palonosetron HCl). Prescribing Information Helsinn Healthcare SA, Lugano, Switzerland; 2009.</mixed-citation></ref><ref id="CR7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bagnes</surname><given-names>C</given-names></name><name><surname>Panchuk</surname><given-names>PN</given-names></name><name><surname>Recondo</surname><given-names>G</given-names></name></person-group><article-title>Antineoplastic chemotherapy induced QTc prolongation</article-title><source>Curr Drug Saf</source><year>2010</year><volume>5</volume><issue>1</issue><fpage>93</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.2174/157488610789869111</pub-id><pub-id pub-id-type="pmid">20210725</pub-id></element-citation></ref><ref id="CR8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basch</surname><given-names>E</given-names></name><name><surname>Prestrud</surname><given-names>AA</given-names></name><name><surname>Hesketh</surname><given-names>PJ</given-names></name><name><surname>Kris</surname><given-names>MG</given-names></name><name><surname>Feyer</surname><given-names>PC</given-names></name><name><surname>Somerfield</surname><given-names>MR</given-names></name><name><surname>Chesney</surname><given-names>M</given-names></name><name><surname>Clark-Snow</surname><given-names>RA</given-names></name><name><surname>Flaherty</surname><given-names>AM</given-names></name><name><surname>Freundlich</surname><given-names>B</given-names></name><name><surname>Morrow</surname><given-names>G</given-names></name><name><surname>Rao</surname><given-names>KV</given-names></name><name><surname>Schwartz</surname><given-names>RN</given-names></name><name><surname>Lyman</surname><given-names>GH</given-names></name><collab>American Society of Clinical Oncology</collab></person-group><article-title>Antiemetics: American Society of Clinical Oncology clinical practice guideline update</article-title><source>J Clin Oncol</source><year>2011</year><volume>29</volume><issue>31</issue><fpage>4189</fpage><lpage>4198</lpage><pub-id pub-id-type="doi">10.1200/JCO.2010.34.4614</pub-id><pub-id pub-id-type="pmid">21947834</pub-id></element-citation></ref><ref id="CR9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benedict</surname><given-names>CR</given-names></name><name><surname>Arbogast</surname><given-names>R</given-names></name><name><surname>Martin</surname><given-names>L</given-names></name><name><surname>Patton</surname><given-names>L</given-names></name><name><surname>Morrill</surname><given-names>B</given-names></name><name><surname>Hahne</surname><given-names>W</given-names></name></person-group><article-title>Single-blind study of the effects of intravenous dolasetron mesylate versus ondansetron on electrocardiographic parameters in normal volunteers</article-title><source>J Cardiovasc Pharmacol</source><year>1996</year><volume>28</volume><issue>1</issue><fpage>53</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1097/00005344-199607000-00009</pub-id><pub-id pub-id-type="pmid">8797136</pub-id></element-citation></ref><ref id="CR10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bloechl-Daum</surname><given-names>B</given-names></name><name><surname>Deuson</surname><given-names>RR</given-names></name><name><surname>Mavros</surname><given-names>P</given-names></name><name><surname>Hansen</surname><given-names>M</given-names></name><name><surname>Herrstedt</surname><given-names>J</given-names></name></person-group><article-title>Delayed nausea and vomiting continue to reduce patients&#x02019; quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment</article-title><source>J Clin Oncol</source><year>2006</year><volume>24</volume><issue>27</issue><fpage>4472</fpage><lpage>4478</lpage><pub-id pub-id-type="doi">10.1200/JCO.2006.05.6382</pub-id><pub-id pub-id-type="pmid">16983116</pub-id></element-citation></ref><ref id="CR11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charbit</surname><given-names>B</given-names></name><name><surname>Albaladejo</surname><given-names>P</given-names></name><name><surname>Funck-Brentano</surname><given-names>C</given-names></name><name><surname>Legrand</surname><given-names>M</given-names></name><name><surname>Samain</surname><given-names>E</given-names></name><name><surname>Marty</surname><given-names>J</given-names></name></person-group><article-title>Prolongation of QTc interval after postoperative nausea and vomiting treatment by droperidol or ondansetron</article-title><source>Anesthesiology</source><year>2005</year><volume>102</volume><issue>6</issue><fpage>1094</fpage><lpage>1100</lpage><pub-id pub-id-type="doi">10.1097/00000542-200506000-00006</pub-id><pub-id pub-id-type="pmid">15915019</pub-id></element-citation></ref><ref id="CR12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charbit</surname><given-names>B</given-names></name><name><surname>Alvarez</surname><given-names>JC</given-names></name><name><surname>Dasque</surname><given-names>E</given-names></name><name><surname>Abe</surname><given-names>E</given-names></name><name><surname>D&#x000e9;molis</surname><given-names>JL</given-names></name><name><surname>Funck-Brentano</surname><given-names>C</given-names></name></person-group><article-title>Droperidol and ondansetron-induced QT interval prolongation: a clinical drug interaction study</article-title><source>Anesthesiology</source><year>2008</year><volume>109</volume><issue>2</issue><fpage>206</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1097/ALN.0b013e31817fd8c8</pub-id><pub-id pub-id-type="pmid">18648229</pub-id></element-citation></ref><ref id="CR13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>L</given-names></name><name><surname>de Moor</surname><given-names>CA</given-names></name><name><surname>Eisenberg</surname><given-names>P</given-names></name><name><surname>Ming</surname><given-names>EE</given-names></name><name><surname>Hu</surname><given-names>H</given-names></name></person-group><article-title>Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings</article-title><source>Support Care Cancer</source><year>2007</year><volume>15</volume><issue>5</issue><fpage>497</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1007/s00520-006-0173-z</pub-id><pub-id pub-id-type="pmid">17103197</pub-id></element-citation></ref><ref id="CR14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dogan</surname><given-names>U</given-names></name><name><surname>Yavas</surname><given-names>G</given-names></name><name><surname>Tekinalp</surname><given-names>M</given-names></name><name><surname>Yavas</surname><given-names>C</given-names></name><name><surname>Ata</surname><given-names>OY</given-names></name><name><surname>Ozdemir</surname><given-names>K</given-names></name></person-group><article-title>Evaluation of the acute effect of palonosetron on transmural dispersion of myocardial repolarization</article-title><source>Eur Rev Med Pharmacol Sci</source><year>2012</year><volume>16</volume><issue>4</issue><fpage>462</fpage><lpage>468</lpage><pub-id pub-id-type="pmid">22696873</pub-id></element-citation></ref><ref id="CR15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eisenberg</surname><given-names>P</given-names></name><name><surname>Figueroa-Vadillo</surname><given-names>J</given-names></name><name><surname>Zamora</surname><given-names>R</given-names></name><name><surname>Charu</surname><given-names>V</given-names></name><name><surname>Hajdenberg</surname><given-names>J</given-names></name><name><surname>Cartmell</surname><given-names>A</given-names></name><name><surname>Macciocchi</surname><given-names>A</given-names></name><name><surname>Grunberg</surname><given-names>S</given-names></name><collab>99&#x02013;04 Palonosetron Study Group</collab></person-group><article-title>Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron</article-title><source>Cancer</source><year>2003</year><volume>98</volume><issue>11</issue><fpage>2473</fpage><lpage>2482</lpage><pub-id pub-id-type="doi">10.1002/cncr.11817</pub-id><pub-id pub-id-type="pmid">14635083</pub-id></element-citation></ref><ref id="CR16"><mixed-citation publication-type="other">Emend (aprepitant). Prescribing Information Merck &#x00026; Co, Inc, Whitehouse Station, NJ; 2006.</mixed-citation></ref><ref id="CR17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feyer</surname><given-names>P</given-names></name><name><surname>Jordan</surname><given-names>K</given-names></name></person-group><article-title>Update and new trends in antiemetic therapy: the continuing need for novel therapies</article-title><source>Ann Oncol</source><year>2011</year><volume>22</volume><issue>1</issue><fpage>30</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdq600</pub-id><pub-id pub-id-type="pmid">20947707</pub-id></element-citation></ref><ref id="CR18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonullu</surname><given-names>G</given-names></name><name><surname>Demircan</surname><given-names>S</given-names></name><name><surname>Demirag</surname><given-names>MK</given-names></name><name><surname>Erdem</surname><given-names>D</given-names></name><name><surname>Yucel</surname><given-names>I</given-names></name></person-group><article-title>Electrocardiographic findings of palonosetron in cancer patients</article-title><source>Support Care Cancer</source><year>2012</year><volume>20</volume><issue>7</issue><fpage>1435</fpage><lpage>1439</lpage><pub-id pub-id-type="doi">10.1007/s00520-011-1226-5</pub-id><pub-id pub-id-type="pmid">21773677</pub-id></element-citation></ref><ref id="CR19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gralla</surname><given-names>R</given-names></name><name><surname>Lichinitser</surname><given-names>M</given-names></name><name><surname>Van Der Vegt</surname><given-names>S</given-names></name><name><surname>Sleeboom</surname><given-names>H</given-names></name><name><surname>Mezger</surname><given-names>J</given-names></name><name><surname>Peschel</surname><given-names>C</given-names></name><name><surname>Tonini</surname><given-names>G</given-names></name><name><surname>Labianca</surname><given-names>R</given-names></name><name><surname>Macciocchi</surname><given-names>A</given-names></name><name><surname>Aapro</surname><given-names>M</given-names></name></person-group><article-title>Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron</article-title><source>Ann Oncol</source><year>2003</year><volume>14</volume><issue>10</issue><fpage>1570</fpage><lpage>1577</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdg417</pub-id><pub-id pub-id-type="pmid">14504060</pub-id></element-citation></ref><ref id="CR20"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Gralla</surname><given-names>RJ</given-names></name><name><surname>Roila</surname><given-names>F</given-names></name><name><surname>Tonato</surname><given-names>M</given-names></name><name><surname>Herrstedt</surname><given-names>J</given-names></name></person-group><source>MASCC/ESMO antiemetic guideline</source><year>2013</year></element-citation></ref><ref id="CR21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gralla</surname><given-names>RJ</given-names></name><name><surname>Bosnjak</surname><given-names>SM</given-names></name><name><surname>Hontsa</surname><given-names>A</given-names></name><name><surname>Balser</surname><given-names>C</given-names></name><name><surname>Rizzi</surname><given-names>G</given-names></name><name><surname>Rossi</surname><given-names>G</given-names></name><name><surname>Borroni</surname><given-names>ME</given-names></name><name><surname>Jordan</surname><given-names>K</given-names></name></person-group><article-title>A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy</article-title><source>Ann Oncol</source><year>2014</year><volume>25</volume><issue>7</issue><fpage>1333</fpage><lpage>1339</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdu096</pub-id><pub-id pub-id-type="pmid">24631949</pub-id></element-citation></ref><ref id="CR22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haab</surname><given-names>F</given-names></name><name><surname>Braticevici</surname><given-names>B</given-names></name><name><surname>Krivoborodov</surname><given-names>G</given-names></name><name><surname>Palmas</surname><given-names>M</given-names></name><name><surname>Zufferli Russo</surname><given-names>M</given-names></name><name><surname>Pietra</surname><given-names>C</given-names></name></person-group><article-title>Efficacy and safety of repeated dosing of netupitant, a neurokinin-1 receptor antagonist, in treating overactive bladder</article-title><source>Neurourol Urodyn</source><year>2014</year><volume>33</volume><issue>3</issue><fpage>335</fpage><lpage>340</lpage><pub-id pub-id-type="doi">10.1002/nau.22406</pub-id><pub-id pub-id-type="pmid">23765630</pub-id></element-citation></ref><ref id="CR23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hedhli</surname><given-names>N</given-names></name><name><surname>Russell</surname><given-names>KS</given-names></name></person-group><article-title>Cardiotoxicity of molecularly targeted agents</article-title><source>Curr Cardiol Rev</source><year>2011</year><volume>7</volume><issue>4</issue><fpage>221</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.2174/157340311799960636</pub-id><pub-id pub-id-type="pmid">22758623</pub-id></element-citation></ref><ref id="CR24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hesketh</surname><given-names>PJ</given-names></name><name><surname>Van Belle</surname><given-names>S</given-names></name><name><surname>Aapro</surname><given-names>M</given-names></name><name><surname>Tattersall</surname><given-names>FD</given-names></name><name><surname>Naylor</surname><given-names>RJ</given-names></name><name><surname>Hargreaves</surname><given-names>R</given-names></name><name><surname>Carides</surname><given-names>AD</given-names></name><name><surname>Evans</surname><given-names>JK</given-names></name><name><surname>Horgan</surname><given-names>KJ</given-names></name></person-group><article-title>Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists</article-title><source>Eur J Cancer</source><year>2003</year><volume>39</volume><issue>8</issue><fpage>1074</fpage><lpage>1080</lpage><pub-id pub-id-type="doi">10.1016/S0959-8049(02)00674-3</pub-id><pub-id pub-id-type="pmid">12736106</pub-id></element-citation></ref><ref id="CR25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hesketh</surname><given-names>PJ</given-names></name><name><surname>Rossi</surname><given-names>G</given-names></name><name><surname>Rizzi</surname><given-names>G</given-names></name><name><surname>Palmas</surname><given-names>M</given-names></name><name><surname>Alyasova</surname><given-names>A</given-names></name><name><surname>Bondarenko</surname><given-names>I</given-names></name><name><surname>Lisyanskaya</surname><given-names>A</given-names></name><name><surname>Gralla</surname><given-names>RJ</given-names></name></person-group><article-title>Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study</article-title><source>Ann Oncol</source><year>2014</year><volume>25</volume><issue>7</issue><fpage>1340</fpage><lpage>1346</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdu110</pub-id><pub-id pub-id-type="pmid">24608196</pub-id></element-citation></ref><ref id="CR26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>BM</given-names></name><name><surname>Adams</surname><given-names>LM</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Gainer</surname><given-names>SD</given-names></name><name><surname>Kirby</surname><given-names>LC</given-names></name><name><surname>Blum</surname><given-names>RA</given-names></name><name><surname>Apseloff</surname><given-names>G</given-names></name><name><surname>Morrison</surname><given-names>RA</given-names></name><name><surname>Schutz</surname><given-names>RA</given-names></name><name><surname>Lebowitz</surname><given-names>PF</given-names></name></person-group><article-title>Ketoconazole and rifampin significantly affect the pharmacokinetics, but not the safety or QTc interval, of casopitant, a neurokinin-1 receptor antagonist</article-title><source>J Clin Pharmacol</source><year>2010</year><volume>50</volume><issue>8</issue><fpage>951</fpage><lpage>959</lpage><pub-id pub-id-type="doi">10.1177/0091270009353761</pub-id><pub-id pub-id-type="pmid">20124517</pub-id></element-citation></ref><ref id="CR27"><mixed-citation publication-type="other">Kytril (granisetron hydrochloride). Prescribing Information Genentech USA, Inc, South San Francisco, CA; 2011.</mixed-citation></ref><ref id="CR28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marbury</surname><given-names>TC</given-names></name><name><surname>Jin</surname><given-names>B</given-names></name><name><surname>Panebianco</surname><given-names>D</given-names></name><name><surname>Murphy</surname><given-names>MG</given-names></name><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Evans</surname><given-names>JK</given-names></name><name><surname>Han</surname><given-names>TH</given-names></name><name><surname>Constanzer</surname><given-names>ML</given-names></name><name><surname>Dru</surname><given-names>J</given-names></name><name><surname>Shadle</surname><given-names>CR</given-names></name></person-group><article-title>Lack of effect of aprepitant or its prodrug fosaprepitant on QTc intervals in healthy subjects</article-title><source>Anesth Analg</source><year>2009</year><volume>109</volume><issue>2</issue><fpage>418</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.1213/ane.0b013e3181ac1066</pub-id><pub-id pub-id-type="pmid">19608812</pub-id></element-citation></ref><ref id="CR29"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Morganroth</surname><given-names>J</given-names></name><name><surname>Parisi</surname><given-names>S</given-names></name><name><surname>Spinelli</surname><given-names>T</given-names></name><name><surname>Moresino</surname><given-names>C</given-names></name><name><surname>Thorn</surname><given-names>M</given-names></name><name><surname>Cullen</surname><given-names>MT</given-names></name></person-group><source>High-dose palonosetron does not alter ECG parameters including QTc interval in healthy subjects: results of a dose&#x02013;response, double-blind, randomized, parallel E14 study of palonosetron vs moxifloxacin or placebo</source><year>2007</year></element-citation></ref><ref id="CR30"><element-citation publication-type="book"><source>NCCN clinical practice guidelines in oncology (NCCN guidelines) antiemesis version 1.2013</source><year>2013</year></element-citation></ref><ref id="CR31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reddy</surname><given-names>GK</given-names></name><name><surname>Gralla</surname><given-names>RJ</given-names></name><name><surname>Hesketh</surname><given-names>PJ</given-names></name></person-group><article-title>Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis</article-title><source>Support Cancer Ther</source><year>2006</year><volume>3</volume><issue>3</issue><fpage>140</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.3816/SCT.2006.n.011</pub-id><pub-id pub-id-type="pmid">18632487</pub-id></element-citation></ref><ref id="CR32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roila</surname><given-names>F</given-names></name><name><surname>Herrstedt</surname><given-names>J</given-names></name><name><surname>Aapro</surname><given-names>M</given-names></name><name><surname>Gralla</surname><given-names>RJ</given-names></name><name><surname>Einhorn</surname><given-names>LH</given-names></name><name><surname>Ballatori</surname><given-names>E</given-names></name><name><surname>Bria</surname><given-names>E</given-names></name><name><surname>Clark-Snow</surname><given-names>RA</given-names></name><name><surname>Espersen</surname><given-names>BT</given-names></name><name><surname>Feyer</surname><given-names>P</given-names></name><name><surname>Grunberg</surname><given-names>SM</given-names></name><name><surname>Hesketh</surname><given-names>PJ</given-names></name><name><surname>Jordan</surname><given-names>K</given-names></name><name><surname>Kris</surname><given-names>MG</given-names></name><name><surname>Maranzano</surname><given-names>E</given-names></name><name><surname>Molassiotis</surname><given-names>A</given-names></name><name><surname>Morrow</surname><given-names>G</given-names></name><name><surname>Olver</surname><given-names>I</given-names></name><name><surname>Rapoport</surname><given-names>BL</given-names></name><name><surname>Rittenberg</surname><given-names>C</given-names></name><name><surname>Saito</surname><given-names>M</given-names></name><name><surname>Tonato</surname><given-names>M</given-names></name><name><surname>Warr</surname><given-names>D</given-names></name><collab>ESMO/MASCC Guidelines Working Group</collab></person-group><article-title>Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference</article-title><source>Ann Oncol</source><year>2010</year><volume>21</volume><issue>Suppl 5</issue><fpage>v232</fpage><lpage>v243</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdq194</pub-id><pub-id pub-id-type="pmid">20555089</pub-id></element-citation></ref><ref id="CR33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rojas</surname><given-names>C</given-names></name><name><surname>Slusher</surname><given-names>BS</given-names></name></person-group><article-title>Pharmacological mechanisms of 5-HT<sub>3</sub> and tachykinin NK<sub>1</sub> receptor antagonism to prevent chemotherapy-induced nausea and vomiting</article-title><source>Eur J Pharmacol</source><year>2012</year><volume>684</volume><issue>1&#x02013;3</issue><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2012.01.046</pub-id><pub-id pub-id-type="pmid">22425650</pub-id></element-citation></ref><ref id="CR34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roscoe</surname><given-names>JA</given-names></name><name><surname>Morrow</surname><given-names>GR</given-names></name><name><surname>Hickok</surname><given-names>JT</given-names></name><name><surname>Mustian</surname><given-names>KM</given-names></name><name><surname>Shelke</surname><given-names>AR</given-names></name></person-group><article-title>Biobehavioral factors in chemotherapy-induced nausea and vomiting</article-title><source>J Natl Compr Canc Netw</source><year>2004</year><volume>2</volume><issue>5</issue><fpage>501</fpage><lpage>508</lpage><pub-id pub-id-type="pmid">19780257</pub-id></element-citation></ref><ref id="CR35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubenstein</surname><given-names>EB</given-names></name><name><surname>Slusher</surname><given-names>BS</given-names></name><name><surname>Rojas</surname><given-names>C</given-names></name><name><surname>Navari</surname><given-names>RM</given-names></name></person-group><article-title>New approaches to chemotherapy-induced nausea and vomiting: from neuropharmacology to clinical investigations</article-title><source>Cancer J</source><year>2006</year><volume>12</volume><issue>5</issue><fpage>341</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.1097/00130404-200609000-00003</pub-id><pub-id pub-id-type="pmid">17034670</pub-id></element-citation></ref><ref id="CR36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saito</surname><given-names>M</given-names></name><name><surname>Aogi</surname><given-names>K</given-names></name><name><surname>Sekine</surname><given-names>I</given-names></name><name><surname>Yoshizawa</surname><given-names>H</given-names></name><name><surname>Yanagita</surname><given-names>Y</given-names></name><name><surname>Sakai</surname><given-names>H</given-names></name><name><surname>Inoue</surname><given-names>K</given-names></name><name><surname>Kitagawa</surname><given-names>C</given-names></name><name><surname>Ogura</surname><given-names>T</given-names></name><name><surname>Mitsuhashi</surname><given-names>S</given-names></name></person-group><article-title>Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial</article-title><source>Lancet Oncol</source><year>2009</year><volume>10</volume><issue>2</issue><fpage>115</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(08)70313-9</pub-id><pub-id pub-id-type="pmid">19135415</pub-id></element-citation></ref><ref id="CR37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salsman</surname><given-names>JM</given-names></name><name><surname>Grunberg</surname><given-names>SM</given-names></name><name><surname>Beaumont</surname><given-names>JL</given-names></name><name><surname>Rogers</surname><given-names>M</given-names></name><name><surname>Paul</surname><given-names>D</given-names></name><name><surname>Clayman</surname><given-names>ML</given-names></name><name><surname>Cella</surname><given-names>D</given-names></name></person-group><article-title>Communicating about chemotherapy-induced nausea and vomiting: a comparison of patient and provider perspectives</article-title><source>J Natl Compr Canc Netw</source><year>2012</year><volume>10</volume><issue>2</issue><fpage>149</fpage><lpage>157</lpage><pub-id pub-id-type="pmid">22308514</pub-id></element-citation></ref><ref id="CR38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sorrentino</surname><given-names>MF</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Foderaro</surname><given-names>AE</given-names></name><name><surname>Truesdell</surname><given-names>AG</given-names></name></person-group><article-title>5-fluorouracil induced cardiotoxicity: review of the literature</article-title><source>Cardiol J</source><year>2012</year><volume>19</volume><issue>5</issue><fpage>453</fpage><lpage>458</lpage><pub-id pub-id-type="doi">10.5603/CJ.2012.0084</pub-id><pub-id pub-id-type="pmid">23042307</pub-id></element-citation></ref><ref id="CR39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spinelli</surname><given-names>T</given-names></name><name><surname>Calcagnile</surname><given-names>S</given-names></name><name><surname>Giuliano</surname><given-names>C</given-names></name><name><surname>Rossi</surname><given-names>G</given-names></name><name><surname>Lanzarotti</surname><given-names>C</given-names></name><name><surname>Mair</surname><given-names>S</given-names></name><name><surname>Stevens</surname><given-names>L</given-names></name><name><surname>Nisbet</surname><given-names>I</given-names></name></person-group><article-title>Netupitant PET imaging and ADME studies in humans</article-title><source>J Clin Pharmacol</source><year>2014</year><volume>54</volume><issue>1</issue><fpage>97</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1002/jcph.198</pub-id><pub-id pub-id-type="pmid">24122871</pub-id></element-citation></ref><ref id="CR40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stathis</surname><given-names>M</given-names></name><name><surname>Pietra</surname><given-names>C</given-names></name><name><surname>Rojas</surname><given-names>C</given-names></name><name><surname>Slusher</surname><given-names>BS</given-names></name></person-group><article-title>Inhibition of substance P-mediated responses in NG108-15 cells by netupitant and palonosetron exhibit synergistic effects</article-title><source>Eur J Pharmacol</source><year>2012</year><volume>689</volume><issue>1&#x02013;3</issue><fpage>25</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2012.05.037</pub-id><pub-id pub-id-type="pmid">22683863</pub-id></element-citation></ref><ref id="CR41"><element-citation publication-type="book"><source>Guidance for industry. E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs (ICH E14)</source><year>2005</year></element-citation></ref><ref id="CR42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vo</surname><given-names>TT</given-names></name><name><surname>Nelson</surname><given-names>JJ</given-names></name></person-group><article-title>Cardiovascular events in cancer patients treated with highly or moderately emetogenic chemotherapy: results from a population-based study</article-title><source>J Cancer Epidemiol</source><year>2012</year><volume>2012</volume><fpage>529357</fpage><pub-id pub-id-type="doi">10.1155/2012/529357</pub-id><pub-id pub-id-type="pmid">22570656</pub-id></element-citation></ref><ref id="CR43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yavas</surname><given-names>C</given-names></name><name><surname>Dogan</surname><given-names>U</given-names></name><name><surname>Yavas</surname><given-names>G</given-names></name><name><surname>Araz</surname><given-names>M</given-names></name><name><surname>Ata</surname><given-names>OY</given-names></name></person-group><article-title>Acute effect of palonosetron on electrocardiographic parameters in cancer patients: a prospective study</article-title><source>Support Care Cancer</source><year>2012</year><volume>20</volume><issue>10</issue><fpage>2343</fpage><lpage>2347</lpage><pub-id pub-id-type="doi">10.1007/s00520-011-1348-9</pub-id><pub-id pub-id-type="pmid">22170340</pub-id></element-citation></ref><ref id="CR44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeh</surname><given-names>ET</given-names></name><name><surname>Bickford</surname><given-names>CL</given-names></name></person-group><article-title>Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management</article-title><source>J Am Coll Cardiol</source><year>2009</year><volume>53</volume><issue>24</issue><fpage>2231</fpage><lpage>2247</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2009.02.050</pub-id><pub-id pub-id-type="pmid">19520246</pub-id></element-citation></ref><ref id="CR45"><element-citation publication-type="book"><source>Research Triangle Park, NC: GlaxoSmithKline</source><year>2011</year></element-citation></ref></ref-list></back></article>